Cargando…

Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020

A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 se...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogogiannidou, Zacharoula, Speletas, Matthaios, Vontas, Alexandros, Nikoulis, Dimitrios J., Dadouli, Katerina, Kyritsi, Maria A., Mouchtouri, Varvara A., Mina, Paraskevi, Anagnostopoulos, Lemonia, Koureas, Michalis, Karavasilis, Vasileios, Nikou, Olga, Pinaka, Ourania, Thomaidis, Pavlos C., Kadoglou, Kornilia, Bedevis, Konstantinos, Spyrou, Natalia, Eleftheriou, Alexandros A., Papaevangelou, Vassiliki, Gikas, Achilleas, Vatopoulos, Alkiviadis, Ntzani, Evangelia E., Prezerakos, Panagiotis, Tsiodras, Sotirios, Hadjichristodoulou, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152765/
https://www.ncbi.nlm.nih.gov/pubmed/34068100
http://dx.doi.org/10.3390/vaccines9050504
_version_ 1783698664544272384
author Bogogiannidou, Zacharoula
Speletas, Matthaios
Vontas, Alexandros
Nikoulis, Dimitrios J.
Dadouli, Katerina
Kyritsi, Maria A.
Mouchtouri, Varvara A.
Mina, Paraskevi
Anagnostopoulos, Lemonia
Koureas, Michalis
Karavasilis, Vasileios
Nikou, Olga
Pinaka, Ourania
Thomaidis, Pavlos C.
Kadoglou, Kornilia
Bedevis, Konstantinos
Spyrou, Natalia
Eleftheriou, Alexandros A.
Papaevangelou, Vassiliki
Gikas, Achilleas
Vatopoulos, Alkiviadis
Ntzani, Evangelia E.
Prezerakos, Panagiotis
Tsiodras, Sotirios
Hadjichristodoulou, Christos
author_facet Bogogiannidou, Zacharoula
Speletas, Matthaios
Vontas, Alexandros
Nikoulis, Dimitrios J.
Dadouli, Katerina
Kyritsi, Maria A.
Mouchtouri, Varvara A.
Mina, Paraskevi
Anagnostopoulos, Lemonia
Koureas, Michalis
Karavasilis, Vasileios
Nikou, Olga
Pinaka, Ourania
Thomaidis, Pavlos C.
Kadoglou, Kornilia
Bedevis, Konstantinos
Spyrou, Natalia
Eleftheriou, Alexandros A.
Papaevangelou, Vassiliki
Gikas, Achilleas
Vatopoulos, Alkiviadis
Ntzani, Evangelia E.
Prezerakos, Panagiotis
Tsiodras, Sotirios
Hadjichristodoulou, Christos
author_sort Bogogiannidou, Zacharoula
collection PubMed
description A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 serum samples collected, 89 (0.44%) were found to be positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (0.35%) observed in May 2020. The highest seroprevalence was primarily observed in the “30–49” year age group. Females presented higher seroprevalence compared to males in May 2020 (females: 0.58% VS males: 0.10%). This difference reversed during the study period and males presented a higher proportion in August 2020 (females: 0.12% VS males: 0.58%). Differences in the rate of seropositivity between urban areas and the rest of the country were also observed during the study period. The four-month infection fatality rate (IFR) was estimated to be 0.47%, while the respective case fatality rate (CFR) was at 1.89%. Our findings confirm low seroprevalence of COVID-19 in Greece during the study period. The young adults are presented as the most affected age group. The loss of the cumulative effect of seropositivity in a proportion of previous SARS-CoV-2 infections was indicated.
format Online
Article
Text
id pubmed-8152765
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81527652021-05-27 Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020 Bogogiannidou, Zacharoula Speletas, Matthaios Vontas, Alexandros Nikoulis, Dimitrios J. Dadouli, Katerina Kyritsi, Maria A. Mouchtouri, Varvara A. Mina, Paraskevi Anagnostopoulos, Lemonia Koureas, Michalis Karavasilis, Vasileios Nikou, Olga Pinaka, Ourania Thomaidis, Pavlos C. Kadoglou, Kornilia Bedevis, Konstantinos Spyrou, Natalia Eleftheriou, Alexandros A. Papaevangelou, Vassiliki Gikas, Achilleas Vatopoulos, Alkiviadis Ntzani, Evangelia E. Prezerakos, Panagiotis Tsiodras, Sotirios Hadjichristodoulou, Christos Vaccines (Basel) Article A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 serum samples collected, 89 (0.44%) were found to be positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (0.35%) observed in May 2020. The highest seroprevalence was primarily observed in the “30–49” year age group. Females presented higher seroprevalence compared to males in May 2020 (females: 0.58% VS males: 0.10%). This difference reversed during the study period and males presented a higher proportion in August 2020 (females: 0.12% VS males: 0.58%). Differences in the rate of seropositivity between urban areas and the rest of the country were also observed during the study period. The four-month infection fatality rate (IFR) was estimated to be 0.47%, while the respective case fatality rate (CFR) was at 1.89%. Our findings confirm low seroprevalence of COVID-19 in Greece during the study period. The young adults are presented as the most affected age group. The loss of the cumulative effect of seropositivity in a proportion of previous SARS-CoV-2 infections was indicated. MDPI 2021-05-13 /pmc/articles/PMC8152765/ /pubmed/34068100 http://dx.doi.org/10.3390/vaccines9050504 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bogogiannidou, Zacharoula
Speletas, Matthaios
Vontas, Alexandros
Nikoulis, Dimitrios J.
Dadouli, Katerina
Kyritsi, Maria A.
Mouchtouri, Varvara A.
Mina, Paraskevi
Anagnostopoulos, Lemonia
Koureas, Michalis
Karavasilis, Vasileios
Nikou, Olga
Pinaka, Ourania
Thomaidis, Pavlos C.
Kadoglou, Kornilia
Bedevis, Konstantinos
Spyrou, Natalia
Eleftheriou, Alexandros A.
Papaevangelou, Vassiliki
Gikas, Achilleas
Vatopoulos, Alkiviadis
Ntzani, Evangelia E.
Prezerakos, Panagiotis
Tsiodras, Sotirios
Hadjichristodoulou, Christos
Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020
title Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020
title_full Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020
title_fullStr Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020
title_full_unstemmed Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020
title_short Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020
title_sort repeated leftover serosurvey of sars-cov-2 igg antibodies in greece, may to august 2020
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152765/
https://www.ncbi.nlm.nih.gov/pubmed/34068100
http://dx.doi.org/10.3390/vaccines9050504
work_keys_str_mv AT bogogiannidouzacharoula repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT speletasmatthaios repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT vontasalexandros repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT nikoulisdimitriosj repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT dadoulikaterina repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT kyritsimariaa repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT mouchtourivarvaraa repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT minaparaskevi repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT anagnostopouloslemonia repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT koureasmichalis repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT karavasilisvasileios repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT nikouolga repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT pinakaourania repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT thomaidispavlosc repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT kadogloukornilia repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT bedeviskonstantinos repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT spyrounatalia repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT eleftherioualexandrosa repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT papaevangelouvassiliki repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT gikasachilleas repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT vatopoulosalkiviadis repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT ntzanievangeliae repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT prezerakospanagiotis repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT tsiodrassotirios repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020
AT hadjichristodoulouchristos repeatedleftoverserosurveyofsarscov2iggantibodiesingreecemaytoaugust2020